Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"ImmuneOncia Therapeutics, Inc","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"$8.0 million","newsHeadline":"ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"D","amount":"$202.0 million","upfrontCash":"$7.5 million","newsHeadline":"SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by 3D Medicines Corporation

    Menu

    3D Medicines Corporation

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              3D Medicines Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China

              Details:

              3D189 or SLS-001 (galinpepimut-S), is an immunotherapeutic that targets the Wilms Tumor 1 (WT1) protein which is present and over-expressed in an array of hematological malignancies and solid tumors.

              Lead Product(s): Galinpepimut-S,Sargramostim

              Therapeutic Area: Oncology Product Name: SLS-001

              Highest Development Status: Phase III Product Type: Vaccine

              Recipient: Sellas Life Sciences Group

              Deal Size: $202.0 million Upfront Cash: $7.5 million

              Deal Type: Licensing Agreement April 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              3D Medicines Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China

              Details:

              The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan).

              Lead Product(s): IgG4 monoclonal antibody

              Therapeutic Area: Oncology Product Name: IMC-002

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: ImmuneOncia Therapeutics, Inc

              Deal Size: $470.0 million Upfront Cash: $8.0 million

              Deal Type: Collaboration March 31, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY